BAIYA PHYTOPHARM

Recombinant Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody (CR3022)

Product Information

Product Overview	Recombinant Anti-SARS-CoV-2 spike protein Glycoprotein S1 antibody was expressed in *Nicotiana benthamiana*.
Description	Human monoclonal (CR3022) to SARS-CoV-2 Spike Glycoprotein S1
Sources	*Nicotiana benthamiana*
Host Species	Human
Tested applications	Suitable for: ELISA, Western blot
Species reactivity	React with: SARS-CoV, SARS-CoV-2
Description	The original CR3022 antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV. This antibody was shown to neutralize SARS-COV in a concerted action with clone CR3014. Presence of both antibodies delivers a blocking action of the SARS-COV RBD-ACE2 interaction, by binding two distinct and functional epitopes[1]. CR3022 is the anti SARS-COV neutralising antibody that crosses react with SARS-CoV2. Structural modelling has confirmed that CR3022 targets a conserved epitope between SARS-CoV and SARS-CoV2 in the RBD domain[2,3]. Recombinant Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody is a Human IgG1 Recombinant version of CR3022 for research use only.
Form	Supplied as 0.22μm filtered solution in PBS (pH7.4)
Purity	Protein A purified
Clonality	Monoclonal
Isotype	IgG1
Light chain type	kappa
Formulation	Liquid
Component	PBS, pH7.4
Storage	Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze/thaw cycle.
Note	**For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.**

SDS-PAGE



IN VITRO Binding Assay



CR3022 mAb can bind to SARS-CoV-2 Spike protein.

References

1. ter Meulen J, van der Brink EN, Poon LL, Marissen WE, Leung CS, Cox F, Cheung CY, Bakker AQ, Bogaards JA, van Deventer E, Preiser W, Doerr HW, Chow VT, de Kruif J, Peiris JS, and Goudsmit J. Human monoclonal antibody combination against SARS coronavirus: synergisty and coverage of escape mutants. PLOS Med. 2006;3(7):e237.
2. Yuan M, Wu NC, Zhu X, Lee CD, So RTY, Lv H, Mok CKP, and Wilson IA. Science. 2020;368(6491):630-633.
3. Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, Lu L, Jiang S, Yang Z, Wu Y, and Ying T. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020;9(1):382-384.